A rapid and non-invasive nasal swab test has been created by researchers to identify the immune system triggers causing a child’s asthma. This discovery may result in more focused and efficient therapies for this prevalent ailment.
According to the National Institutes of Health, asthma is the most common chronic illness in children and affects roughly 10% of children in the US. It is by no means a universally applicable sickness, though. Depending on the cause of the airway inflammation, it differs significantly from child to child. Understanding these variations—also referred to as asthma endotypes or subtypes—is essential to knowing how to treat each individual instance.
As per the source “The first step to improving therapy is an accurate diagnosis of the asthma endotype,” said Dr. Juan Celedon, chief of pulmonary medicine at UPMC Children’s Hospital of Pittsburgh. “There are many different endotypes of asthma, each driven by a different immune cell and responding differently to treatment.”
In the past, intrusive techniques, such obtaining a lung tissue sample while the child is sedated, have been necessary to diagnose these endotypes. In addition to being costly, these tests are not feasible for kids with mild asthma. In order to establish an educated guess on a child’s asthma subtype, clinicians have been forced to rely on less accurate techniques including blood testing and lung function evaluations.
An easier and more accurate substitute is the novel nasal swab test, which was detailed in a study that was published in the Journal of the American Medical Association. Nearly 460 children’s nasal samples were examined by researchers, who concentrated on eight particular genes connected to immune cells that cause inflammation in asthma.
Children from African American and Puerto Rican families were included in the study because their asthma rates are higher and their outcomes are worse. The nasal swab test correctly determined if a child had low-low, T2-high, or T17-high asthma, which was encouraging.
Targeted therapies are currently available for T2-high asthma; a well-studied subtype caused by T helper 2 cells.
There are presently no particular treatments for low-low asthma, where neither cell type is predominant or T17-high asthma, which is brought on by T helper 17 cells.
The test could revolutionize the treatment of children with T2-high asthma by pointing them toward potent new drugs that target the immune cells that cause the illness. Nearly 29% of the children in the study fit this description, according to the researchers.
According to Dr. Celedon, this new test may also help researchers better understand the T17-high and low-low subtypes. He declared, “At this point, we can begin creating therapies for these endotypes.”
The test may also help explain the differences in asthma outcomes during puberty. “Asthma is more common in boys before puberty, but it increases in girls in age,” Celedon said.
-Raja Aditya
